bmjourBaikal Medical JournalБайкальский медицинский журнал2949-0715Irkutsk State Medical University10.57256/2949-0715-2022-1-33-40bmjour-19Research ArticleOriginal articlesОригинальные статьиASSOCIATION OF GALECTIN-3 WITH FACTORS OF DECOMPENSATION OF CHRONIC HEART FAILURE IN PATIENTS WITH OSTEOARTHRITISОЦЕНКА АССОЦИАЦИИ ГАЛЕКТИНА-3 С ФАКТОРАМИ ДЕКОМПЕНСАЦИИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У ПАЦИЕНТОВ С ОСТЕОАРТРИТОМhttps://orcid.org/0000-0002-5188-7997АнкудиновАндрей СергеевичAnkudinov A.S.
доцент кафедры симуляционных технологий и экстренной медицинской помощи ФГБОУ ВО ИГМУ, к.м.н., доцент
SPIN CODE 2235-1846
andruhin.box@ya.ruФГБОУ ВО Иркутский государственный медицинский университет Минздрава России
ОГБУЗ Иркутская городская клиническая больница №1Russian Federation202210122022113340Copyright © Ankudinov A.С., 20222022Анкудинов А.С.Ankudinov A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bmjour.ru/jour/article/view/19
he negative impact of chronic inflammation on the onset and progression of endothelial dysfunction, blood pressure destabilization and renal function deterioration is widely discussed by modern researchers. One of the topical lines of research is studying the effect of osteoarthritis (OA) on the course of chronic heart failure (CHF). Using modern immunological cytokines in the treatment of such patients can contribute to an earlier diagnosis of the risk of decom-pensation of the cardiovascular pathology.The aim of the study. To study the possibilities of using galectin-3 in CHF patients with preserved and moderately reduced left ventricular ejection fraction and osteoarthritis in combination with CHF decompensation factors.Materials and methods. A cross-sectional study of 107 CHF patients was carried out: 60 patients formed the study group with combination of CHF and OA; 47 patients were included in comparison group with CHF and without OA. A comparative analysis of clinical, laboratory and instrumental parameters, as well as of the galectin-3 level was car-ried out. The relationship between galectin-3 and CHF decompensation factors in the study group was analyzed, and its diagnostic capabilities were assessed. Statistical processing was carried out using the Statistica 10.0 program (StatSoft Inc., USA). The critical level of statistical significance was p < 0.05.Results. According to the results of the study, in the study group, a statistically significantly higher level of galectin-3 was revealed compared to the one in patients of the comparison group – 42 ± 2.2 and 20 ± 1.5 ng/ml respectively (p < 0.001), as well as statistically significant associations of galectin-3 with blood pressure levels, dyslipidemia, esti-mated glomerular filtration rate, and atrial natriuretic peptide.Conclusion. The presence of a statistically significant association of galectin-3 with CHF decompensation factors in patients with osteoarthritis reveals new pathogenetic features of the course of this comorbid pathology. Apparently, it is possible to use galectin-3 as a marker for diagnosing decompensation in this group of patients.
Негативное воздействие хронического воспаления на возникновение и прогрессирование эндотелиальной дис-функции, дестабилизацию уровня артериального давления, ухудшение почечной функции широко обсуждается современными исследователями. Одним из актуальных направлений является изучение влияния остеоартрита (ОА) на течение хронической сердечной недостаточности (ХСН). Применение современных иммунологических цитокинов у данной группы пациентов может способствовать более ранней диагностике риска декомпенсации основной сердечно-сосудистой патологии.Цель исследования. Изучить возможности использования галектина-3 у больных ХСН с сохранённой и уме-ренно сниженной фракцией выброса левого желудочка и ОА в комбинации с факторами декомпенсации ХСН. Материалы и методы. Проведено одномоментное поперечное исследование 107 пациентов с ХСН: 60 паци-ентов – исследуемая группа (ХСН и ОА); 47 пациентов – группа сравнения (ХСН без ОА). Проведён сравни-тельный анализ клинических лабораторных и инструментальных показателей, а также уровня галектина-3. Проанализирована взаимосвязь галектина-3 с факторами декомпенсации ХСН в исследуемой группе, оценены его диагностические возможности. Статистическая обработка проводилась с использованием программы Statistica 10.0 (StatSoft Inc., США). Критический уровень значимости при проверке статистических гипотез р < 0,05.Результаты. По результатам проведённого исследования в группе ХСН и ОА выявлен статистически значимо более высокий уровень галектина-3 по отношению к пациентам группы сравнения – 42 ± 2,2 и 20 ± 1,5 нг/мл соответственно (р < 0,001), а также статистически значимые ассоциации галектина-3 с уровнями артериаль-ного давления, дислипидемией, расчётной скоростью клубочковой фильтрации и предсердного натрийуре-тического пептида. Заключение. Наличие статистически значимой ассоциации галектина-3 с факторами декомпенсации ХСН у пациентов с ОА раскрывает новые патогенетические особенности течения данной коморбидной патологии. По всей видимости, использование галектина-3 возможно в качестве маркера диагностики декомпенсации у данной группы пациентов.
he negative impact of chronic inflammation on the onset and progression of endothelial dysfunction, blood pressure destabilization and renal function deterioration is widely discussed by modern researchers. One of the topical lines of research is studying the effect of osteoarthritis (OA) on the course of chronic heart failure (CHF). Using modern immunological cytokines in the treatment of such patients can contribute to an earlier diagnosis of the risk of decom-pensation of the cardiovascular pathology.The aim of the study. To study the possibilities of using galectin-3 in CHF patients with preserved and moderately reduced left ventricular ejection fraction and osteoarthritis in combination with CHF decompensation factors.Materials and methods. A cross-sectional study of 107 CHF patients was carried out: 60 patients formed the study group with combination of CHF and OA; 47 patients were included in comparison group with CHF and without OA. A comparative analysis of clinical, laboratory and instrumental parameters, as well as of the galectin-3 level was car-ried out. The relationship between galectin-3 and CHF decompensation factors in the study group was analyzed, and its diagnostic capabilities were assessed. Statistical processing was carried out using the Statistica 10.0 program (StatSoft Inc., USA). The critical level of statistical significance was p < 0.05.Results. According to the results of the study, in the study group, a statistically significantly higher level of galectin-3 was revealed compared to the one in patients of the comparison group – 42 ± 2.2 and 20 ± 1.5 ng/ml respectively (p < 0.001), as well as statistically significant associations of galectin-3 with blood pressure levels, dyslipidemia, esti-mated glomerular filtration rate, and atrial natriuretic peptide.Conclusion. The presence of a statistically significant association of galectin-3 with CHF decompensation factors in patients with osteoarthritis reveals new pathogenetic features of the course of this comorbid pathology. Apparently, it is possible to use galectin-3 as a marker for diagnosing decompensation in this group of patients.
ReferencesMiao Q., Zhang Y.L., Miao Q.F. et al. Sudden Death from Ischemic Heart Disease While Driving: Cardiac Pathology, Clinical Characteristics, and Countermeasures. Med Sci Monit. 2021;27:e929212. https://doi.org/10.12659/MSM.929212Miao Q., Zhang Y.L., Miao Q.F. et al. Sudden Death from Ischemic Heart Disease While Driving: Cardiac Pathology, Clinical Characteristics, and Countermeasures. Med Sci Monit. 2021;27:e929212. https://doi.org/10.12659/MSM.929212Кабалык М.А., Невзорова В.А. Кардиоваскулярные заболевания и остеоартрит: общие механизмы развития, перспективы совместной профилактики и терапии. Кардиоваскулярная терапия и профилактика. 2021;20(1):26-60 [Kabalyk M.A., Nevzorova V.A. Cardiovascular diseases and osteoarthritis: general mechanisms of development, prospects for joint prevention and therapy. Cardiovascular therapy and prevention. 2021;20(1):26-60 (In Russian)]. https://doi.org/10.15829/1728-8800-2021-2660Kabalyk M.A., Nevzorova V.A. Cardiovascular diseases and osteoarthritis: general mechanisms of development, prospects for joint prevention and therapy. Cardiovascular therapy and prevention. 2021;20(1):26-60 (In Russian). https://doi.org/10.15829/1728-8800-2021-2660Wallace I.J., Worthington S., Felson D.T. et al. Knee osteoarthritis has doubled inWallace I.J., Worthington S., Felson D.T. et al. Knee osteoarthritis has doubled inprevalence since the mid-20th century. Proceedings of the National Academy of Sciences. 2017;114 (35):9332-36. https://doi.org/10.1073/pnas.1703856114prevalence since the mid-20th century. Proceedings of the National Academy of Sciences. 2017;114 (35):9332-36. https://doi.org/10.1073/pnas.1703856114Albasri A., OʼSullivan J.W., Roberts N.W. et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017;35(10):1919-1928. https://doi.org/10.1097/HJH.0000000000001443Albasri A., OʼSullivan J.W., Roberts N.W. et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017;35(10):1919-1928. https://doi.org/10.1097/HJH.0000000000001443Weinmann D., Kenn M., Schmidt S. et al. Galectin-8 induces functional disease markers in human osteoarthritis and cooperates with galectins-1 and -3. Cell Mol Life Sci. 2018;75(22):4187-05. https://doi.org/10.1007/s00018-018-2856-2Weinmann D., Kenn M., Schmidt S. et al. Galectin-8 induces functional disease markers in human osteoarthritis and cooperates with galectins-1 and -3. Cell Mol Life Sci. 2018;75(22):4187-05. https://doi.org/10.1007/s00018-018-2856-2Hu Y., Yéléhé-Okouma M., Ea H.K. et al. Galectin-3: a key player in arthritis. Joint Bone Spine. 2017;84(1):15‒20. https://doi.org/10.1016/j.jbspin.2016.02.029Hu Y., Yéléhé-Okouma M., Ea H.K. et al. Galectin-3: a key player in arthritis. Joint Bone Spine. 2017;84(1):15‒20. https://doi.org/10.1016/j.jbspin.2016.02.029Andrews A.R., Fernandes A.D., Brownmiller S.E. et al. Share Blocking extracellular galectin-3 in patients with osteoarthritis. Contemp Clin Trials Commun. 2019;17:100500. https://doi.org/10.1016/j.conctc.2019.100500Andrews A.R., Fernandes A.D., Brownmiller S.E. et al. Share Blocking extracellular galectin-3 in patients with osteoarthritis. Contemp Clin Trials Commun. 2019;17:100500. https://doi.org/10.1016/j.conctc.2019.100500Gehlken C., Suthahar N., Meijers W.C. et al. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin. 2018;14(1):75‒92. https://doi.org/10.1016/j.hfc.2017.08.009Gehlken C., Suthahar N., Meijers W.C. et al. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin. 2018;14(1):75‒92. https://doi.org/10.1016/j.hfc.2017.08.009Zhong X., Qian X., Chen G. et al. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019;46(3):197‒203. https://doi.org/10.1111/1440-1681.13048Zhong X., Qian X., Chen G. et al. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019;46(3):197‒203. https://doi.org/10.1111/1440-1681.13048Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083 [Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083 (In Russian)]. https://doi.org/10.15829/1560-4071-2020-4083Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083 (In Russian). https://doi.org/10.15829/1560-4071-2020-4083Насонов Е.Л. Ревматология. Клинические рекомендации. М.:ГЭОТАР-Медиа;2017:464 [Nasonov E.L. Rheumatology. Clinical recommendations. M.:GEOTAR-Media;2017:464 (In Russian)].Nasonov E.L. Rheumatology. Clinical recommendations. M.:GEOTAR-Media;2017:464 (In Russian).Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.:МедиаСфера;2002:312 [Rebrova O.Y. Statistical analysis of medical data. Application of the STATISTICA application software package. M.:Mediasphere;2002:312 (In Russian)].Rebrova O.Y. Statistical analysis of medical data. Application of the STATISTICA application software package. M.:Mediasphere;2002:312 (In Russian).Berenbaum F., Griffin T.M., Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheum. 2017;69(1):9‒21. https://doi.org/10.1002/art.39842Berenbaum F., Griffin T.M., Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheum. 2017;69(1):9‒21. https://doi.org/10.1002/art.39842Calay E.S., Hotamisligil G.S. Turning off the inflammatory, but not the metabolic, flames. Nat. Med. 2013;19:265‒67. https://doi.org/10.1038/nm.3114Calay E.S., Hotamisligil G.S. Turning off the inflammatory, but not the metabolic, flames. Nat. Med. 2013;19:265‒67. https://doi.org/10.1038/nm.3114Nurmohamed M.T., Heslinga M., Kitas G.D. Cardiovascular comorbidity in rheumatic disease. Nature Reviews Rheumatology. 2015;11(12):693-704. https://doi.org/10.1038/nrrheum.2015.112Nurmohamed M.T., Heslinga M., Kitas G.D. Cardiovascular comorbidity in rheumatic disease. Nature Reviews Rheumatology. 2015;11(12):693-704. https://doi.org/10.1038/nrrheum.2015.112
The authors declare that there are no conflicts of interest present.